USPTO serial 88602178
CUREVAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 13, 2021
- Examiner
- MARTIN, LIEF ANDREW
- Law office
- TMO LAW OFFICE 112
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CUREVAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
TÜBINGEN, DE
Tübingen, DE
Tübingen, DE
Tübingen, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Fraser
Jennifer Fraser DYKEMA GOSSETT PLLC1301 K STREET, NWSUITE 1100 WESTWASHINGTON, DC 20005Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical reagents and biomolecules, in particular biological macromolecules, for industrial or scientific purposes; Reagents for research purposes | ACTIVE | — |
| 005 | Chemical preparations for medical use, namely, for therapeutic and prophylactic treatment of neurological, neuromuscular, neurodegenerative, infectious and cardiovascular diseases, of autoimmune diseases and cancer diseases, of tumours, of allergies, of metabolic diseases, of heritable genetic diseases, and for therapies replacing proteins or enzymes; pharmaceutical preparations, namely, immunostimulants, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, vaccines, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, adjuvant immunostimulants; pharmaceuticals and medicaments containing biological macromolecules, in particular for human or veterinary purposes for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment of infectious diseases, autoimmune diseases and tumours, for treatment of cancers, for treatment of metabolic diseases and for treatment of heritable genetic diseases and for protein or enzyme replacement therapy; gene therapy products, namely, nucleic acid macromolecules for in vivo expression for human or veterinary medical use; Dietetic substances adapted for medical use, in particular substances for food supplements, namely, dietary food supplements; Peptide carrier molecules for association with a biological macromolecule, for medical use, namely, for use in facilitating delivery of a wide range of medicinal substances; Peptidic carrier molecule for preparing a pharmaceutical composition, namely, for medical use as a protein delivery preparation to expedite or improve delivery of a therapeutic macromolecule or prophylactic biological marcomolecule; Peptide carrier molecule, sold in combination with a biological macromolecule for preparing a pharmaceutical composition, namely, for medical use as a protein delivery preparation to expedite or improve delivery of a therapeutic drug or prophylactic drug | ACTIVE | — |
| 042 | Scientific and technological services and research, in particular scientific research for identification, testing and characterisation of biological macromolecules; medical testing services, namely, pre-clinical and clinical testing of macromolecules; scientific research in the nature of discovery of biological macromolecules; Laboratory services, related to custom manufacturing of pharmaceutical ingredients, for identification, testing and characterisation of biological macromolecules | ACTIVE | — |
| 044 | Medical and veterinary services, in particular for therapeutic and prophylactic treatment of cancer diseases, infectious diseases, autoimmune diseases or allergies; Medical and veterinary services for treating of hereditary disorders; Medical and veterinary services for protein or enzyme supplement therapy for therapeutic or prophylactic treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases and for treatment of endocrinological or metabolic disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CUREVAC SE
- Other trademarks owned by CureVac AG
- Other trademarks owned by CureVac AG
- Other trademarks owned by CureVac AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CUREVAC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 13, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 8, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 30, 2021 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Sep 30, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 30, 2021 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Apr 13, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 26, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 26, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 6, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 17, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 30, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 30, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 30, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 15, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jun 4, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 9, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 5, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 14, 2019 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 13, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 6, 2019 | NWAP | NEW APPLICATION ENTERED | — |